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Background
Anti-MCV antibodies (Ab) have high sensitivity and prog-
nostic value in patients with RA. We attempt to correlate
positive anti-MCV Ab in different subtypes of JIA patients
with six core outcome variables.
Patients and methods
Anti-MCV Ab and Anti-CCP Ab were tested by ELISA
(Orgentec, Germany) in sera from 57 JIA, and 14 control
patients (12 patients with SLE, 1 with MCTD and 1 with
synovial cyst). (16 boys, 41 girls), The mean age was 11,2
years (range 2,5–18,0), and mean disease duration was 3,
4 years (SD ± 2.9). Cut off value ≥ 20 U/mL was consid-
ered positive.
Results
Positive anti-MCV Ab were detected in only 3/58 (5,2%)
JIA patients, and were significantly elevated in two RF pos-
itive polyartritis patients, and slightly elevated in 1/19
(5,3%) patients with enthesitis-related arthritis (ErA).
Among all patients, anti-CCP Ab were positive only in one
anti-MCV positive polyarticular JIA patient. Anti-MCV
and RF positivity correlated statistically (r = 0,504, P =
0,028) in ErA, while no association between anti-MCV Ab
and six core outcome variables was observed in this, or
other JIA subtypes. Unexpectedly, anti-MCV was detected
in 3/12 (25%) SLE patients (2 low positive and 1 signifi-
cantly positive), and in 1 patient with MCTD. All of these
patients were both RF and anti-CCP negative.
Conclusion
In contrast to RA, anti-MCV antibodies are not specific for
JIA. However, within JIA patients, significantly elevated
levels are almost exclusively found in two RF positive, pol-
yarticular patients.
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